Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells

…, JT Lam, PJ Mahasreshti, SD Barker, M Straughn… - Clinical Cancer …, 2002 - AACR
Gene delivery efficiency in clinical cancer gene therapy trials with recombinant adenoviruses
(Ads) based on serotype 5 (Ad5) has been limited partly because of variable expression of …

Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy

JM Estes, CA Leath III, MJ Straughn Jr… - Journal of the …, 2006 - journals.lww.com
BACKGROUND: Our goal was to determine the morbidity, disease-free survival, and overall
survival of patients with bowel resection at primary cytoreductive surgery for advanced …

The Wnt/β-catenin pathway in ovarian cancer: a review

RC Arend, AI Londoño-Joshi, JM Straughn Jr… - Gynecologic …, 2013 - Elsevier
Objective Ovarian cancer is the deadliest gynecologic malignancy and the fifth leading cause
of death from cancer in women in the US Since overall survival remains poor, there is a …

At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis

…, KE Resnick, DM O'Malley, JM Straughn Jr - Journal of Clinical …, 2011 - ascopubs.org
Purpose To determine whether the addition of bevacizumab to paclitaxel and carboplatin for
the primary treatment of advanced ovarian cancer can be cost effective. Methods A cost-…

Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer

…, B Hidalgo, RD Alvarez, CN Landen, JM Straughn… - Gynecologic …, 2014 - Elsevier
Objective. The Wnt/β-catenin pathway is known to regulate cellular proliferation and plays a
role in chemoresistance. Niclosamide, an FDA approved salicyclamide derivative used for …

A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer

AS Case, RP Rocconi, JM Straughn Jr… - Obstetrics & …, 2006 - journals.lww.com
OBJECTIVE: To prospectively evaluate in a blinded fashion the accuracy of frozen section in
endometrial cancer. METHODS: Sixty patients with endometrial cancer or complex atypical …

Validation of a venous thromboembolism risk assessment model in gynecologic oncology

…, E Reed, L Bazzett-Matabele, JM Straughn Jr… - Gynecologic …, 2014 - Elsevier
Objectives Gynecologic oncology patients undergoing surgery are at an increased risk for
venous thromboembolism (VTE). We attempted to validate a VTE risk assessment model in …

Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy

WK Huh, M Powell, CA Leath III, JM Straughn Jr… - Gynecologic …, 2003 - Elsevier
OBJECTIVE: Our aim was to determine the outcomes of Stage I uterine papillary serous
carcinoma (UPSC) patients with and without adjuvant therapy after comprehensive surgical …

Conservative management of stage I endometrial carcinoma after surgical staging

JM Straughn Jr, WK Huh, FJ Kelly, CA Leath III… - Gynecologic …, 2002 - Elsevier
Objective. The aim of this study was to determine the outcomes of Stage I endometrial
carcinoma patients who are managed without adjuvant radiation after comprehensive surgical …

Dose escalation and dosimetry of first-in-human α radioimmunotherapy with 212Pb-TCMC-trastuzumab

…, P Bunch, D Morgan, J Fan, JM Straughn - Journal of Nuclear …, 2014 - Soc Nuclear Med
Our purpose was to study the safety, distribution, pharmacokinetics, immunogenicity, and
tumor response of intraperitoneal 212 Pb-TCMC-trastuzumab (TCMC is S-2-(4-…